These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 32777322)

  • 21. Estimates on HCV disease burden worldwide - filling the gaps.
    Wedemeyer H; Dore GJ; Ward JW
    J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    GBD 2017 Cirrhosis Collaborators
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):245-266. PubMed ID: 31981519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030.
    van Dijk M; Brakenhoff SM; Isfordink CJ; Cheng WH; Blokzijl H; Boland G; Dofferhoff ASM; van Hoek B; van Nieuwkoop C; Sonneveld MJ; van der Valk M; Drenth JPH; de Knegt RJ
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling Progress Toward Elimination of Hepatitis B in Australia.
    McCulloch K; Romero N; MacLachlan J; Allard N; Cowie B
    Hepatology; 2020 Apr; 71(4):1170-1181. PubMed ID: 31419332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey.
    Kondili LA; Buti M; Riveiro-Barciela M; Maticic M; Negro F; Berg T; Craxì A
    JHEP Rep; 2022 Sep; 4(9):100531. PubMed ID: 35967191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study.
    Luo Q; O'Connell DL; Yu XQ; Kahn C; Caruana M; Pesola F; Sasieni P; Grogan PB; Aranda S; Cabasag CJ; Soerjomataram I; Steinberg J; Canfell K
    Lancet Public Health; 2022 Jun; 7(6):e537-e548. PubMed ID: 35660215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    Schaefer B; Viveiros A; Al-Zoairy R; Blach S; Brandon S; Razavi H; Dorn L; Finkenstedt A; Effenberger M; Graziadei I; Sarcletti M; Tilg H; Zoller H
    PLoS One; 2018; 13(7):e0200750. PubMed ID: 30001427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
    PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan.
    Chhatwal J; Chen Q; Wang X; Ayer T; Zhuo Y; Janjua NZ; Kanwal F
    JAMA Netw Open; 2019 May; 2(5):e193613. PubMed ID: 31074817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    GBD 2019 Hepatitis B Collaborators
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):796-829. PubMed ID: 35738290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030.
    Howell J; Pedrana A; Cowie BC; Doyle J; Getahun A; Ward J; Gane E; Cunningham C; Wallace J; Lee A; Malani J; Thompson A; Hellard ME
    J Gastroenterol Hepatol; 2019 Jan; 34(1):40-48. PubMed ID: 30151932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study.
    Barocas JA; Savinkina A; Lodi S; Epstein RL; Bouton TC; Sperring H; Hsu HE; Jacobson KR; Schechter-Perkins EM; Linas BP; White LF
    Clin Infect Dis; 2022 Aug; 75(1):e1112-e1119. PubMed ID: 34499124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
    PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model.
    Binka M; Janjua NZ; Grebely J; Estes C; Schanzer D; Kwon JA; Shoukry NH; Kwong JC; Razavi H; Feld JJ; Krajden M
    JAMA Netw Open; 2020 May; 3(5):e204192. PubMed ID: 32374397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.
    Mennini FS; Marcellusi A; Robbins Scott S; Montilla S; Craxi A; Buti M; Gheorghe L; Ryder S; Kondili LA
    Liver Int; 2021 May; 41(5):934-948. PubMed ID: 33529499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
    Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
    MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination.
    Lim AG; Qureshi H; Mahmood H; Hamid S; Davies CF; Trickey A; Glass N; Saeed Q; Fraser H; Walker JG; Mukandavire C; Hickman M; Martin NK; May MT; Averhoff F; Vickerman P
    Int J Epidemiol; 2018 Apr; 47(2):550-560. PubMed ID: 29309592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring hepatitis C virus elimination as a public health threat: Beyond global targets.
    van Santen DK; Sacks-Davis R; Doyle JS; Scott N; Prins M; Hellard M
    J Viral Hepat; 2020 Aug; 27(8):770-773. PubMed ID: 32187431
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.